Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Assets Average (2022 - 2026)

Axsome Therapeutics' Assets Average history spans 5 years, with the latest figure at $701.7 million for Q1 2026.

  • On a quarterly basis, Assets Average rose 20.45% to $701.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $701.7 million, a 20.45% increase, with the full-year FY2025 number at $629.2 million, up 8.78% from a year prior.
  • Assets Average hit $701.7 million in Q1 2026 for Axsome Therapeutics, up from $679.5 million in the prior quarter.
  • Over the last five years, Assets Average for AXSM hit a ceiling of $701.7 million in Q1 2026 and a floor of $88.2 million in Q1 2022.
  • Historically, Assets Average has averaged $491.2 million across 5 years, with a median of $565.0 million in 2024.
  • Biggest five-year swings in Assets Average: soared 308.66% in 2023 and later dropped 8.48% in 2024.
  • Tracing AXSM's Assets Average over 5 years: stood at $335.2 million in 2022, then soared by 77.36% to $594.5 million in 2023, then fell by 4.97% to $565.0 million in 2024, then rose by 20.28% to $679.5 million in 2025, then grew by 3.26% to $701.7 million in 2026.
  • Business Quant data shows Assets Average for AXSM at $701.7 million in Q1 2026, $679.5 million in Q4 2025, and $654.5 million in Q3 2025.